New drug cocktail aims to beat rare lymphoma without chemo
NCT ID NCT07299331
First seen Jan 04, 2026 · Last updated May 02, 2026 · Updated 23 times
Summary
This study tests whether a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) can effectively treat marginal zone lymphoma in people who have not received prior therapy. About 50 adults aged 18-75 with advanced disease will take the drugs and be monitored regularly. The goal is to see if this approach improves remission rates and survival compared to standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA(MZL) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.